Brought to you by 
Forest gets exclusive rights to azimilide from Blue Ash, Warner Chilcott
27 Oct 2020
Executive Summary
Forest Laboratories Inc. (cardiovascular, CNS, respiratory, and infectious disease therapeutics) has gained global rights from cardiovascular drug developer Blue Ash Therapeutics LLC to once-daily orally administered azimilide (sold in Asian markets as Stedicor), which is in Phase III for ventricular arrhythmia patients who need an implantable cardioverter-defibrillator.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest gets exclusive rights to azimilide from Blue Ash, Warner Chilcott
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice